Kun Chang | Urological Oncology| Best Researcher Award

ย Dr. Kun Chang| Urological Oncology | Best Researcher Award

 

๐Ÿ‘จโ€๐ŸซProfessional Summaryย ๐ŸŒŸ

๐ŸŽ“ Ph.D. graduate in Urological Oncology with expertise in Ubiquitination and Tumorigenesis from Fudan University, Shanghai. ๐Ÿฅ Currently, an Attending Urologist at Fudan University Shanghai Cancer Center, building on a comprehensive Residency experience from July 2018 to June 2021. ๐ŸŒ Actively engaged in groundbreaking research, exploring the mechanisms of SPOP-mediated non-degradable ubiquitination in prostate cancer. ๐Ÿงช Passionate about advancing understanding in the field and contributing to cutting-edge studies. ๐Ÿš€ Excited to leverage skills and knowledge for further advancements in urological oncology. #UrologyExpert #ResearchInnovator

๐ŸŒ Professional Profiles

๐ŸŽ“ ย Education & Training

Ph.D., Sep 2015 – Jun 2018 Research Interests: Urological oncology, Ubiquitination, Tumorigenesis Fudan University, Shanghai, China. State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P.R. China. M.D., Sep 2012 – Jun 2015 Research Interests: Urological oncology Fudan University, Shanghai, China

๐Ÿ”ฌ ย Researcher & Professional Experience

Residency at Fudan University Shanghai Cancer Center, July 2018-June 2021, Attending Urologist at Fudan University Shanghai Cancer Center, July 2021-

๐Ÿ” Charge Topic Researcher

Study on the mechanism of SPOP-mediated non-degradable ubiquitination modification of ARHGAP29 in regulating the Hippo pathway in prostate cancer. Shanghai Sailing Program (Grant No. 19YF 1408600) Study on the mechanism of SPOP-mediated ZMYND8 non-degradable ubiquitin-modification in prostate cancer to regulate DNA damage response. Natural Science Foundation of China (Grant No. 81902614)

๐Ÿ“šTop Noted Publication

 

  • Title: Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma
    • Authors: W. Xu, J. Lu, X. Tian, S. Ye, S. Wei, J. Wang, A. Anwaier, Y. Qu, W. Liu, K. Chang, H. Zhang, D. Ye
    • Journal: MedComm(2020), 5 (2024) e461
    • Co-correspondence, IF: 9.9

 

 

  • Title: Plasma proteomic profiling discovers molecular features associated with upper tract urothelial carcinoma
    • Authors: Y. Qu, Z. Yao, N. Xu, G. Shi, J. Su, S. Ye, K. Chang, K. Li, Y. Wang, S. Tan, X. Pei, Y. Chen, Z. Qin, J. Feng, J. Lv, J. Zhu, F. Ma, S. Tang, W. Xu, X. Tian, A. Anwaier, S. Tian, W. Xu, X. Wu, S. Zhu, Y. Zhu, D. Cao, M. Sun, H. Gan, J. Zhao, H. Zhang, D. Ye, C. Ding
    • Journal: Cell Rep Med, 4 (2023) 101166
    • Co-first, IF: 14.3

 

 

  • Title: The expression and prognostic value of transporter 1, ATP binding cassette subfamily B member in clear cell renal cell cancer with experimental validation
    • Authors: Z.D. Wang, X. Tian, Y. Wang, J.J. Wang, S.Q. Ye, Y.Q. Huang, Y.Y. Qu, K. Chang, G.H. Shi, D.W. Ye, C.Y. Gu
    • Journal: Front Oncol, 12 (2022) 1013790
    • Co-correspondence, IF: 5.738

 

  • Title: Construction of an Immune Escape-Related Signature in Clear Cell Renal Cell Carcinoma and Identification of the Relationship between IFNAR1 and Immune Infiltration by Multiple Immunohistochemistry
    • Authors: K. Chang, F. Xu, X. Zhang, B. Zeng, W. Zhang, G. Shi, D. Ye
    • Journal: Cancers (Basel), 15 (2022)
    • Co-first, IF: 6.575

 

 

  • Title: Development and validation of a mitochondrial metabolism-associated nomogram for prediction of prognosis in clear cell renal cell carcinoma
    • Authors: B. Zeng, Y. Huang, S. Jin, X. Zhang, H. Zhang, G. Shi, D. Cao, K. Chang, B. Dai, D. Ye
    • Journal: Clin Transl Med, 10 (2020) e120
    • Co-correspondence, IF: 7.919